Project Grant R01CA308826
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $548K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Miami, FL 33136, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded the Regents of the University of Michigan $571,735 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA312636). The award funds research into mechanisms by which collagen extracellular matrix disruption potentiates anti-glioma immune responses. The project combines collagen inhibition with immune-stimulatory gene therapy—specifically AD-HSV1-TK to increase tumor antigen release and...
- The National Cancer Institute awarded the University of Miami $614,453 on August 24, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing Number) to develop anti-ST2 theranostic nanobodies for colorectal cancer immunotherapy. The award funds development and characterization of murine and human single-domain antibodies (nanobodies) targeting ST2 (interleukin-33 receptor), a novel immune checkpoint target for advanced colorectal cancer. Work includes generating...
- The National Cancer Institute awarded Northwestern University $496,357 under the Cancer Treatment Research program (CFDA 93.395) on April 17, 2026, to investigate mechanisms of immunosuppression in glioblastoma and develop therapeutic interventions targeting tumor-associated macrophage polarization. The research centers on the peri-necrotic niche within IDH-wildtype glioblastoma tumors, where hypoxic glioma cells and immunosuppressive tumor-associated macrophages aggregate in spatial...
- The National Institutes of Health National Cancer Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $707,798 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to determine mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches. The research identifies transcriptional, genetic, neuronal, and immunological factors influencing glioblastoma formation, progression, and treatment response,...
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Cancer Institute awarded the University of Florida $502,391 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop RNA-loaded lipid-nanoparticle aggregates (RNA-LPAs) as an mRNA vaccine therapy for glioblastoma. The project, designated R01CA314365, will generate a multilamellar "onion-like" nanoparticle formulation that layers glioma antigens into RNA-LPA structures. Preliminary data indicate that systemic administration of these aggregates...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded The Trustees of Columbia University in the City of New York $702,132 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics screening aimed at identifying small molecule modulators of tumor cell-intrinsic immunogenicity in glioblastoma. The research program will expose glioblastoma neurosphere models to 3,792 small...
- The National Institutes of Health National Cancer Institute awarded $687,314 to Mayo Clinic Jacksonville on July 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate senescence and resistance mechanisms in glioblastoma and to develop combination therapeutic strategies that overcome drug resistance. The funded research examines how glioblastomas develop resistance to mitotic kinase and kinesin inhibitors (ispinesib, alisertib, volasertib, and etoposide) through...
- The National Cancer Institute awarded The Ohio State University $567,754 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on immunotherapy for glioblastoma by targeting an immunoregulatory neuropeptide. The research addresses glioblastoma (GBM), the most lethal primary brain tumor, which exhibits remarkable resistance to immunotherapy due to CD8 T cell exclusion and dysfunction driven by immunosuppressive myeloid cells, particularly tumor-associated...
- The National Cancer Institute awarded the University of Miami $164,190 under the Cancer Research Manpower program (CFDA 93.398) on December 17, 2025, to support biomedical training in basic, clinical, and prevention research relevant to the National Cancer Program. The project, titled "Immuno-Modulating Diffuse Midline Glioma by Epi-Transcriptomic Reprogramming," runs through September 1, 2029, with performance at the University of Miami's Office of Research Administration—School of...